A randomized pilot study of naturopathic medicine in multiple sclerosis

Journal of Alternative and Complementary Medicine

Volumn 14, Issue 5, 2008, Pages 489-496

  Shinto, Lynne ^a   Calabrese, Carlo ^b   Morris, Cynthia ^c   Yadav, Vijayshree ^a   Griffith, Debbie ^a   Frank, Rachel ^a   Oken, Barry S ^a   Baldauf Wagner, Sara ^a   Bourdette, Dennis ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b National College of Natural Medicine   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CYANOCOBALAMIN; FISH OIL; THIOCTIC ACID;

ALTERNATIVE MEDICINE; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; EXPANDED DISABILITY STATUS SCALE; HEALTH SURVEY; HUMAN; LABORATORY TEST; MULTIPLE SCLEROSIS; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; VITAMIN SUPPLEMENTATION;

ADULT; ATTITUDE TO HEALTH; COGNITION DISORDERS; DEPRESSION; FATIGUE; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NATUROPATHY; PILOT PROJECTS; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 45749137594     PISSN: 10755535     EISSN: None     Source Type: Journal    
DOI: 10.1089/acm.2007.0757     Document Type: Article

References (26)

1. Noseworthy J, Lucchinetti C, Rodriguez M, Weinshenker B. Multiple sclerosis. N Engl J Med 2000;343:938-952.
2. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992;10:153-187.
3. Hafler DA, Weiner HL. Immunologic mechanisms and therapy in multiple sclerosis. Immunol Rev 1995;144:75-107.
4. Filippini G, Munari L, Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis: A systematic review. Lancet 2003;361:545-552.
5. Berkman C, Pignotti M, Cavallo P, Holland N. Use of alternative treatments by people with multiple sclerosis. Neurorehabil Neural Repair 1999;13:243-254.
6. Schwartz CE, Laitin E, Brotman S, LaRocca N. Utilization of unconventional treatments by persons with MS: Is it alternative or complementary? Neurology 1999;52:626-629.
7. Nayak S, Matheis RJ, Schoenberger NE, Shiflett SC. Use of unconventional therapies by individuals with multiple sclerosis. Clin Rehabil 2003;17:181-191.
8. Page SA, Verhoef MJ, Stebbins RA, et al. The use of complementary and alternative therapies by people with multiple sclerosis. Chronic Dis Can 2003;24:75-79.
9. Stuifbergen AK, Harrison TC. Complementary and alternative therapy use in persons with multiple sclerosis. Rehabil Nurs 2003;28:141-147, 158.
10. Yadav V, Shinto L, Morris C, et al. Use and self reported benefit of complementary and alternative medicine (CAM) among multiple sclerosis patients. Int J MS Care 2006;8:5-10.
11. Shinto L, Calabrese C. Naturopathic therapies for neurological disorders. In: Oken B, ed. Complementary Therapies in Neurology: An Evidence-Based Approach. London: CRC-Press-Parthenon Publishing Group, 2003:127-143.
12. Marrie RA, Hadjimichael O, Vollmer T. Predictors of alternative medicine use by multiple sclerosis patients. Mult Scler 2003;9:461-466.
13. Shinto L, Calabrese C, Morris C, et al. Complementary and alternative medicine in multiple sclerosis: Survey of licensed naturopaths. J Altern Complement Med 2004;10:891-897.
14. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983;13:227-231.
15. Kurtzke J. Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
16. Fischer JS, LaRocca NG, Miller DM, et al. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult Scler 1999;5:251-259.
17. Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): An integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999;5:244-250.
18. Rudick RA, Cutter G, Reingold S. The multiple sclerosis functional composite: A new clinical outcome measure for multiple sclerosis trials. Mult Scler 2002;8:359-365.
19. Gronwall DMA. Paced auditory serial-addition task: A measure of recovery from concussion. Percept Mot Skills 1977;44:356-373.
20. Perret E. The left frontal lobe of man and the suppression of habitual responses in verbal categorical behaviour. Neuropsychologia 1974;12:323-330.
21. Beck A, Ward CH, Medelson M, Mock J. An inventory for measuring depression. Archives of General Psychiatry 1961;4:561-571.
22. Fisk JD, Ritvo PG, Ross L, et al. Measuring the functional impact of fatigue: Initial validation of the fatigue impact scale. Clin Infect Dis 1994;18(suppl 1):S79-S83.
23. Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315-325.
24. Nelson M. The validation of dietary assessment. In: Margetts BM, Nelson M, eds. Design Concepts in Nutritional Epidemiology. New York: Oxford University Press, 1997.
25. Nortvedt MW, Riise T, Myhr KM, Nyland HI. Performance of the SF-36, SF-12, and RAND-36 summary scales in a multiple sclerosis population. Med Care 2000;38:1022-1028.
26. Fan VS, Au DH, McDonell MB, Fihn SD. Intraindividual change in SF-36 in ambulatory clinic primary care patients predicted mortality and hospitalizations. J Clin Epidemiol 2004;57:277-283.